Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.

Mingzhi ZhangDan ChenXiaorui FuHuimin MengFeifei NanZhenchang SunHui YuLei ZhangLing LiXin LiXinhua WangMin WangFengtao YouZhaoming LiYu ChangZhiyuan ZhouJiaqin YanJiwei LiXiaolong WuYu WangYinyan WangShufen XiangYuSheng ChenGuifang PanHanying XuBozhen ZhangLin Yang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Autologous nanobody-derived fratricide-resistant CD7-CAR T cells demonstrated a promising and durable antitumor response in R/R T-ALL/LBL with tolerable toxicity, warranting further studies in highly aggressive CD7-positive malignancies.

Keyphrases

acute lymphoblastic leukemia
diffuse large b cell lymphoma
bone marrow
nk cells
cell therapy
acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
oxidative stress
multiple myeloma
case control